Skip to main content
. 2020 Jul 14;11(28):2747–2762. doi: 10.18632/oncotarget.27668

Figure 1. TMEM165 is increased in many human cancers and correlates with reduced overall survival.

Figure 1

(A) Amplification of TMEM165 in human cancers in the cBioPortal [58, 59]. (B) Analysis of TMEM165 expression levels in molecular subtypes of human breast cancer using UALCAN. (C) Kaplan–Meier analysis (http://kmplot.com/analysis/index) of OS was plotted for breast cancer patients (n = 626). The OS was determined to be significantly longer in the TMEM165 low expression group than in the TMEM165 high expression group. A cutoff value of 1495 was chosen by auto select in the analysis configuration, with the expression value of the probe (218095_s_at) ranging from 89 to 8312. Upper quartile survival rates (months) for the low and high expression groups were 143 and 68.4, respectively.